September 2021
In this issue
Complimentary webinars and podcasts, thought-provoking articles, industry news, and more!
Mitigate risks with a stepwise approach to first-in-human trials.
Five Ways Altasciences Simplifies the Drug Development Process for You
Discover how Altasciences relieves you of the need to plan and manage the many elements of early phase drug development, for hassle-free outsourcing.
Benefits of Using Liquid-Filled Capsules in Clinical Trials
Discover why two-piece, liquid-filled, hard-shell capsules (LFCs) are the solution formulation scientists are looking to for turning poorly soluble small molecules into viable development candidates.
Emyria Limited Partners with Altasciences to Accelerate FDA and TGA CBD Registration
Read this article to learn more about the partnership, which could lead to the first over-the-counter CBD medicine available in Australia.
Calvert Labs, an Altasciences Company, has been selected to design and conduct exploratory studies for Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PRNTM) program.
New Podcast Series: “The Many Faces of Recreational Drug Use”
The series is a collection of candid conversations with study participants about their personal drug use history, both with recreational drug use and with substance use disorder. Throughout the conversations, Altasciences’ Dr. Beatrice Setnik, Chief Scientific Officer, and Dr. Debra Kelsh, MD, Senior Principal Investigator and Psychologist, pause to discuss key moments in the interviews. Watch the first episode!
In September, Altasciences began a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s disease. The objective of the first-in-human study is to determine the safety, tolerability, and appropriate dosing for future studies.
Altasciences’ Chief Scientific Officer, Dr. Beatrice Setnik, Contributes to a Study on Difelikefalin
This article for the journal Clinical and Translational Science, co-authored by Dr. Setnik, shares the findings of a study that assessed the effect of difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, on key relevant measures of respiratory depression in healthy volunteers.
CONTINUE READING
- Webinars
Catch up on some of our favorite on-demand webinars. - Podcasts
Listen to (or watch) our discussions on drug development topics, including an interview with Dr. John Atkinson, Founder of Atkinson Toxicology Consulting, the first episode of “The Many Faces of Recreational Drug Use” series, and a discussion on developing the second generation of psychedelics and their analogs for targeted medical use. - Up Close and Personal With…
Meet Ben Reed, BS, Vice President of Operations for Altasciences’ Manufacturing and Analytical Services. - Blog
Catch up on Altasciences’ latest blog articles on microsampling, ethnobridging, and liquid-filled capsules. - Upcoming Events
See what events we will be attending over the next few weeks.